Viamet Pharmaceuticals and the Novartis Option Fund Enter Agreement for Development of Novel Metalloenzyme Inhibitors

Viamet Pharmaceuticals and the Novartis Option Fund Enter Agreement for Development of Novel Metalloenzyme Inhibitors

Viamet eligible to receive over $200 million in potential milestone payments as well as product royalties

MORRISVILLE, N.C.--(BUSINESS WIRE)--Feb 22, 2010 - Viamet Pharmaceuticals, Inc. announced today that it has entered into a licensing option agreement with the Novartis Option Fund. Under terms of the agreement, Viamet will utilize its proprietary MetallophileTM Technology to discover and develop novel metalloenzyme inhibitors against a specific metalloenzyme of high interest to Novartis. The agreement includes an upfront fee and potential milestones totaling over $200 million as well as product royalties.

"Viamet's MetallophileTM Technology is a powerful platform that enables the rapid and cost-effective generation of best-in-class metalloenzyme inhibitors," stated Lauren Silverman, Ph.D., Managing Director, Novartis Option Fund. "Metalloenzymes are a large class of enzymes, many of which are closely related, and finding inhibitors that are potent yet selective for a specific metalloenzyme can be very challenging. Viamet's MetallophileTM Technology offers the potential for the discovery and development of superior metalloenzyme inhibitors with improved safety and efficacy."

"Partnering with Novartis on this key metalloenzyme target provides Viamet with the opportunity to expand the MetallophileTM Technology beyond our current development programs," commented Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet. "We believe that the MetallophileTM Technology can be applied to all metalloenzymes, which represents a large commercial opportunity that is beyond our capacity to pursue independently. Working with quality partners, such as Novartis, will allow us to fully exploit our technology and realize its full potential."

About Viamet Pharmaceuticals, Inc. (www.viamet.com)

Viamet discovers and develops novel inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the MetallophileTM Technology. Viamet's disruptive MetallophileTM Technology is based on world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify metalloenzyme targets with high therapeutic and commercial potential, leverage existing metalloenzyme inhibitors as the basis for its novel analogs, and rapidly and cost-effectively generate superior compounds by optimizing the metal-binding component of existing inhibitors. Viamet is based in the Research Triangle Park region of North Carolina.

About Novartis Option Fund (www.venturefund.novartis.com)

The Novartis Option Fund is a $200 million fund that is part of the Novartis Corporate Venture Funds. Established in 1996, the Novartis Venture Funds currently manage over $750 million in committed capital and are invested in more than 60 private companies. The objective of the Novartis Option Fund is to seed innovative companies through initial and follow on investment. The initial investment is coupled with an option to a specific therapeutic program providing early validation for the company's technology by a larger pharmaceutical partner. The Novartis Venture Funds team of eight investment professionals located in Basel, Switzerland and Cambridge, Massachusetts, brings together extensive expertise in the biotech and pharmaceutical industry and venture capital.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.